Cocrystal Pharma, Inc.
Clinical trials sponsored by Cocrystal Pharma, Inc., explained in plain language.
Cocrystal Pharma, Inc.
COCP
NASDAQ
Biotech developing antiviral drugs for influenza and hepatitis.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to stop stomach bug in its tracks Results expected Oct 2026 (estimated)